NET ASSET VALUE – 30 November 2024
On the 30 November 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,206 million and NAV per share was SEK 53.88.
|
Allocation of NAV |
Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 486 | 6.23 | 11.6% |
| Xspray Pharma | 18% | 269 | 3.44 | 6.4% |
| KAHR Medical | 31% | 206 | 2.64 | 4.9% |
| Empros Pharma | 79% | 204 | 2.62 | 4.9% |
| Atrogi | 37% | 176 | 2.25 | 4.2% |
| Lipum | 57% | 171 | 2.19 | 4.1% |
| Microbiotica | 11% | 138 | 1.77 | 3.3% |
| Geneos Therapeutics | 12% | 105 | 1.34 | 2.5% |
| Xintela | 56% | 104 | 1.34 | 2.5% |
| Mendus | 24% | 101 | 1.30 | 2.4% |
| Toleranzia | 66% | 97 | 1.25 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 57 | 0.73 | 1.4% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.3% |
| AnaCardio | 19% | 52 | 0.66 | 1.2% |
| Egetis Therapeutics | 2% | 38 | 0.49 | 0.9% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Vitara Biomedical | 8% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,380 | 30.49 | 56.6% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.5% |
| Symcel | 31% | 169 | 2.16 | 4.0% |
| Provell Pharmaceuticals | 72% | 78 | 0.99 | 1.8% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Nanologica | 43% | 63 | 0.81 | 1.5% |
| A3P Biomedical | 8% | 42 | 0.54 | 1.0% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 649 | 8.31 | 15.4% | |
| Limited Partnerships, total | 92 | 1.18 | 2.2% | |
| Assets related to Portfolio companies | 299 | 3.84 | 7.1% | |
| Other assets and liabilities | 785 | 10.06 | 18.7% | |
| Net asset value | 4,206 | 53.88 | 100.0% | |
* indirect shares in Provell Pharmaceuticals